Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls

The association of CYP19 gene polymorphisms with breast cancer has been widely reported, but results of previous studies were somewhat contradictory and underpowered. In order to overcome the limitations of individual study and to understand the real situation, we conducted a systematic review and meta-analysis including three CYP19 gene polymorphisms [R264C polymorphism, CYP19_630 3-bp del/Ins polymorphism, and CYP19_681 (TTTA)n polymorphisms]. A total of 22 studies with 10,592 cases and 11,720 controls were identified, and the results showed that R264C polymorphism was not associated with breast cancer risk in overall (T vs. C: OR = 1.061, 95% CI = 0.929–1.212) or race-based populations (T vs. C for Asian: OR = 1.169, 95% CI = 1.002–1.363; for Caucasian: OR = 0.787, 95% CI = 0.597–1.037); meanwhile, for Asian individuals, 3-bpDel/Ins polymorphism showed a significantly association with breast cancer susceptibility (for allele Del vs. allele Ins: OR = 1.278, 95% CI = 1.066–1.532) while the carriers of allele (TTTA)12 can significantly decrease breast cancer risk (OR = 0.752, 95% CI = 0.603–0.939). Furthermore, the carriers of allele (TTTA)10 were significantly associated with breast cancer susceptibility (OR = 1.515, 95% CI = 1.115–2.058). It can be concluded that potentially functional CYP19_630 3-bp del/Ins polymorphism and CYP19_681 (TTTA)n polymorphisms may play a low penetrance role in breast cancer susceptibility in an ethnicity-specific manner.

[1]  H. Hollema,et al.  Aromatase in the context of breast and endometrial cancer. A review. , 2006, Minerva endocrinologica.

[2]  C. V. de Moura Gallo,et al.  CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women. , 2006, Toxicology letters.

[3]  Z. Shao,et al.  A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives , 2007, Journal of Cancer Research and Clinical Oncology.

[4]  Georg Heinze,et al.  Estrogen‐metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women , 2004, Cancer.

[5]  D. Eccles,et al.  Polymorphic variation in CYP19 and the risk of breast cancer. , 2001, Carcinogenesis.

[6]  Raghu Kacker,et al.  Random-effects model for meta-analysis of clinical trials: an update. , 2007, Contemporary clinical trials.

[7]  F. Liu,et al.  Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. , 2005, Chinese medical journal.

[8]  W. Willett,et al.  A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk , 2000, International journal of cancer.

[9]  A. Folsom,et al.  CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. , 2004, Cancer letters.

[10]  A. Børresen-Dale,et al.  A rare CYP19 (aromatase) variant may increase the risk of breast cancer. , 1998, Pharmacogenetics.

[11]  B. Zumoff.  Does Postmenopausal Estrogen Administration Increase the Risk of Breast Cancer? Contributions of Animal, Biochemical, and Clinical Investigative Studies to a Resolution of the Controversy , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[12]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[13]  B. Ponder,et al.  Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. , 2000, Carcinogenesis.

[14]  K. Ickstadt,et al.  Breast cancer: a candidate gene approach across the estrogen metabolic pathway , 2007, Breast Cancer Research and Treatment.

[15]  N. Laird,et al.  Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women , 2009, International journal of cancer.

[16]  N. Probst-Hensch,et al.  Aromatase and breast cancer susceptibility. , 1999, Endocrine-related cancer.

[17]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[18]  D. Noh,et al.  Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women , 2003, British Journal of Cancer.

[19]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[20]  A. Tsatsakis,et al.  A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides. , 2004, Toxicology letters.

[21]  R. Vierkant,et al.  A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches , 2007, Breast Cancer Research and Treatment.

[22]  O. Gotoh,et al.  Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. , 1997, Pharmacogenetics.

[23]  E. Imyanitov,et al.  Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. , 2002, European journal of cancer.

[24]  Y. Miyoshi,et al.  Breast cancer risk associated with polymorphism in CYP19 in Japanese women , 2000, International journal of cancer.

[25]  M. Filipenko,et al.  Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. , 2008, Advances in experimental medicine and biology.

[26]  C. Weinberg,et al.  Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. , 2002, American journal of epidemiology.

[27]  W. Boon,et al.  Aromatase--a brief overview. , 2002, Annual review of physiology.

[28]  K. Buetow,et al.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.